Tinostamustine
- Generic Name
- Tinostamustine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28Cl2N4O2
- CAS Number
- 1236199-60-2
- Unique Ingredient Identifier
- 29DKI2H2NY
- Background
Tinostamustine is under investigation in clinical trial NCT03452930 (Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 12
- Registration Number
- NCT05432375
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, Spain
🇪🇸South Texas Accelerated Research Therapeutics (START), Madrid, Spain
Tinostamustine and Nivolumab in Advanced Melanoma
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Markus Joerger
- Target Recruit Count
- 21
- Registration Number
- NCT03903458
- Locations
- 🇨ðŸ‡
Kantonsspital Graubünden, Chur, Switzerland
🇨ðŸ‡Cantonal Hospital St.Gallen, St.Gallen, Switzerland
Tinostamustine Conditioning and Autologous Stem Cell
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Mundipharma-EDO GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT03687125
- Locations
- 🇨ðŸ‡
Universitatsspital Bern, Bern, Switzerland
🇺🇸Memorial Sloan Kettering Cancer Centre, New York, New York, United States
🇺🇸Carolinas Healthcare System, Charlotte, North Carolina, United States
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03452930
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 106
- Registration Number
- NCT02576496
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸University Hospitals Cleveland Seidman Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.